In addition, CGBIO exhibited a wide range of products across various segments, including AILEENE, GISELLELIGNE, LUXX, DOOTH, ...

RICHMOND, Va., April 06, 2026 (GLOBE NEWSWIRE) -- On March 31, 2026, The Brink’s Company (NYSE:BCO) (“Brink’s”), a leading global provider of cash and valuables management, digital retail solutions ...

XMax Inc (NASDAQ: XWIN, “XMax” or the “Company”) today announced that, further to its Board’s approval of strategic expansion into artificial intelligence (“AI”) as previously announced on March 24, ...

PITTSBURGH, April 06, 2026 (GLOBE NEWSWIRE) -- Duolingo, Inc. (Nasdaq: DUOL), the world's leading mobile learning platform, will announce its results for the first quarter ending March 31, 2026, ...

TORONTO, April 06, 2026 (GLOBE NEWSWIRE) -- AGF Management Limited (TSX:AGF.B) reported total assets under management (AUM) and fee-earning assets 1 of $59.1 billion as at March 31, 2026.

NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- MidCap Financial Investment Corporation (NASDAQ: MFIC) (the “Company”) announced today that it will report results for the quarter ended March 31, 2026, ...

Greif, Inc. (NYSE: GEF, GEF.B), a global leader in industrial packaging products and services, announced today it will report the company’s 2026 second quarter financial results after the market ...

Bureau Veritas acquires Lotusworks, reinforcing its position in data centers and entering the semiconductor sector; this establishes a new c.EUR 300 million growth platform ...

Interested parties may register for the conference call using the following link: Nanox Q4 2025 Call The live webcast of the conference call may be accessed by using the following link: Nanox Q4 2025 ...

MIAMI, April 06, 2026 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (the "Company") (NYSE: PNNT) announced that it will report results for the second fiscal quarter ended March 31, 2026 on ...

Leerink Partners, TD Cowen, Guggenheim Securities and Cantor acted as joint bookrunning managers for the offering. LifeSci Capital and H.C. Wainwright & Co. acted as co-lead managers for the offering.

YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses - YUVIWEL is now commercially ...